Figure 1. SPTBN1 is closely related to the progression of epithelial ovarian cancer. (A) Analysis of TCGA data. The expression of SPTBN1 was significantly decreased as EOC staging increased. NS: stage 1 vs stage 2, 3, and 4; *P<0.05 vs stage 3 and 4; #P<0.05 vs stage 3. (B, C) The progression-free survival (PFS) and overall survival (OS) rates were retrieved from the TCGA dataset (probe 214856_at) and compared between the low-SPTBN1 and high-SPTBN1 ovarian cancer patients. The low-SPTBN1 group had shorter PFS than the high-SPTBN1 group. (D) Expression of SPTBN1 in 8 ovarian cancer cell lines. The expression of SPTBN1 in high-metastasis HO8910-PM cells was lower than that in conventional HO8910 cells, suggesting that the decrease in SPTBN1 expression may be correlated with the increased incidence of malignancy of epithelial ovarian cancer.